Fine-needle Diathermy Combined With Subconjunctival Bevacizumab for Corneal Neovascularization

NCT07642960 | Recruiting DMC

• 1 other identifier: CS/BVM/25/84
• Study Type: interventional
• Target: 51
• Locations: 1 country
• Sites: 1

Brief Summary

The goal of this clinical trial is to evaluate the efficacy and safety of combined fine-needle diathermy and subconjunctival Bevacizumab injection in patients with corneal neovascularization. The main questions it aims to answer are: Does combined fine-needle diathermy and subconjunctival Bevacizumab injection promote regression of corneal neovascularization? Is the treatment safe and well tolerated by patients? Participants will: Undergo a baseline evaluation, including assessment of disease duration, ocular history, systemic medical history, and presenting symptoms. Undergo a detailed ophthalmic evaluation, including best-corrected visual acuity, intraocular pressure measurement, slit-lamp examination, corneal photography, and anterior segment optical coherence tomography (AS-OCT). Provide informed consent after explanation of potential risks and benefits of the procedure.

Conditions

Corneal Neovascularisation

Keywords

Corneal Neovascularization; Fine-Needle Diathermy; Anti-VEGF

Outcome Measures

Primary Outcomes (1)

• Percentage reduction in corneal neovascularization area at 12 months

  Corneal photographs will be obtained at baseline and follow-up visits. The neovascularized corneal area will be measured using ImageJ software. The primary outcome is the percentage reduction in corneal neovascularization area at 12 months compared with baseline following combined fine-needle diathermy and subconjunctival bevacizumab injection.

  12 months

Study Arms (1)

Fine-needle diathermy plus subconjunctival Bevacizumab

EXPERIMENTAL

Participants with corneal neovascularization will receive combined fine-needle diathermy and subconjunctival bevacizumab injection. Fine-needle diathermy will be performed to occlude corneal neovessels, followed by a subconjunctival injection of bevacizumab (2.5 mg/0.1 mL) adjacent to the treated area. Participants will be followed for 12 months to evaluate treatment efficacy and safety.

Procedure: Fine-needle diathermy; Drug: Bevacizumab

Interventions

Fine-needle diathermy PROCEDURE

Fine-needle diathermy is performed under an operating microscope using a 10-0 nylon needle and low-power monopolar diathermy to occlude corneal neovessels.

Fine-needle diathermy plus subconjunctival Bevacizumab

Bevacizumab DRUG

Bevacizumab 2.5 mg/0.1 mL is administered by subconjunctival injection adjacent to the treated corneal neovessels immediately after fine-needle diathermy.

Fine-needle diathermy plus subconjunctival Bevacizumab

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Age over 18 years.
• Diagnosis of corneal neovascularization involving at least one quadrant of the cornea, confirmed by slit-lamp examination.
• Corneal neovascularization is stable with no evidence of progression for at least 4 weeks.
• Agreement to participate in the study and ability to comply with outpatient follow-up requirements

You may not qualify if:

• Pregnant or breastfeeding women.
• History of hypersensitivity or allergy to bevacizumab or any component of the study medication.
• Presence of severe systemic disease that would preclude study participation or surgical intervention, including coagulation disorders or uncontrolled cardiovascular disease.
• Active ocular infection or acute conjunctivitis at the time of enrollment.
• Persistent corneal epithelial defect or delayed corneal epithelial healing.
• History of ocular surgery within 3 months before study enrollment.
• Corneal neovascularization associated with uncontrolled secondary glaucoma.
• Inability or unwillingness to comply with study treatment or follow-up visits.

Sponsors & Collaborators

• HoChiMinh City Eye Hospital: lead

Study Sites (1)

HoChiMinh City Eye Hospital

Ho Chi Minh City, Xuan Hoa, 72400, Vietnam

RECRUITING

MeSH Terms

Conditions

Corneal Neovascularization

Interventions

Bevacizumab

Condition Hierarchy (Ancestors)

Corneal Diseases; Eye Diseases; Neovascularization, Pathologic; Metaplasia; Pathologic Processes; Pathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal; Antibodies; Immunoglobulins; Immunoproteins; Blood Proteins; Proteins; Amino Acids, Peptides, and Proteins; Serum Globulins; Globulins

Study Officials

• Minh Nhat Le, Master of Ophthalmology

  HoChiMinh City Eye Hospital

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Minh Nhat Le, Master of Ophthalmology

CONTACT

+84833399368; le.nminh93@gmail.com

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Lecturer And Ophthalmologist

Study Record Dates

• First Submitted: June 6, 2026
• First Posted: June 11, 2026
• Study Start: April 1, 2026
• Primary Completion (Estimated): April 1, 2028
• Study Completion (Estimated): April 1, 2028
• Last Updated: June 11, 2026

Record last verified: 2026-06

Locations

VN (1)